Background/Purpose: This study aims to study the factors that affect the stamina of elderly patients during trospium treatment. Methods: To carry out the experiment, 843 men and women older than 60 years (average age, 68.4 years) who had been taking trospium for 12 months were selected. The questionnaire survey on demographic and social status, financial statement analysis, academic certificates, Overactive bladder Questionnaire short form and Medical Outcomes Study-Short Form questionnaires, bladder diaries, and uroflowmetry were used for studies of adherence to treatment. Results: The average time of reaching the 30-day trospium-treatment-free period (compliance "survival rate") was 191 days. The percentage of patients who remained compliant for 6 months and 1 year were 58.3% and 44.0%, respectively. According to our data, the percentage of highly educated (59.3%), married (63.8%), and city (70.6%) residents who are aware of the nature of their disease (77.5%) are significantly higher in the cohort of consistent patients; yet the percentage of caffeine abusers is lower (10.9%). In this cohort, the percentage of income spent on trospium purchase (3.1%) was lower, but income and payment level for medical expenses were higher (p 0.05 and p 0.01, respectively, compared with other cohorts). An analysis of regressive models of changes in squared percentage of income and trospium costs has confirmed the hypothesis of the impact of these factors on treatment compliance. In the cohort of consistent patients, the average number of points of role physical, social functioning, role emotional, and mental health values that describe the health impact on the quality of life turned out to be significantly higher. Severe incontinence symptoms (70.8%) and overactive bladder (35.9%) prevailed among patients of this cohort, which were also associated with high treatment efficacy and a significantly lower number of side effects (9.3%). Conclusion: High trospium treatment compliance among elderly men and women is determined by several uneven demographic, social, economic, and medical factors.
Introduction
The morbidity of lower urinary tract symptoms (LUTS), including overactive bladder (OAB) symptoms, among people is very high. LUTS have, at least occasionally, been reported in 26e33% of men and 27e46% of women of all races. 1 LUTS is known to have an adverse impact on the health-related quality of life. 2, 3 Besides, the significant prevalence of LUTS is due to its high economic costs. 4, 5 The main lineup of drugs for LUTS treatment is still considered to comprise antimuscarinic (AM) drugs. Among AM drugs, trospium chloride, a quaternary ammonium compound that neither penetrates the bloodebrain barrier nor affects the central nervous system, has been widely used. It allows the avoidance of adverse side effects and increases demand for trospium during treatment of various forms of LUTS, particularly among elderly persons. 6, 7 However, when studying the efficacy and safety of various trospium dosages among elderly patients who suffered from different forms of LUTS in our previous experiments, we noticed poor patient compliance with treatment. Moreover, on adherence affect not only medical factors. 8, 9 According to most researchers, absence of results, side effects, and dosage regimen are attributable to medical factors that cause low compliance. 10e12 Yet some researchers point to polymorbidity, poor awareness of patients, and some other factors as important factors that contribute to the loss of compliance. 13, 14 A number of researchers cast reasonable doubt on the fact that pharmacological properties of various AM drugs affect treatment compliance level. 15 However, the issue of balance of various factors' impact on patient compliance to therapy with AM drugs, particularly trospium chloride, has been studied incompletely. Most of the available studies have been carried out in a retrospective way, without any correlation between trospium intake, a particular diagnosis, and diagnosis verification by special methods. Given these circumstances, in this experiment, we set the goal of studying heterogeneous factors that affect the stamina of elderly patients who suffer from different forms of LUTS during trospium chloride treatment to increase the manageability of OAB symptoms.
Methods

General information
A randomized blind prospective study on factors affecting the stamina of older patients during their trospium treatment was carried out from January 4, 2012 to January 6, 2014 at the Regional Clinical Diagnosis Center, City Outpatient Hospital Number 3, and a geriatric hospital located in Vladivostok City, Russia. A total of 843 patients (449 women and 394 men; age range, 60e87 years) participated in the experiment. The average age was 68.4 years. To "blind" the research team dealing with statistical analysis of obtained data arrays, data files were impersonalized by assigning random numbers and personal data were deleted. Stratified randomization allowed a roughly even representation of men and women during patient selection.
Scope of selection was calculated with reference to confidence probability of 95% and confidence interval of ±5%.
Inclusion/exclusion criteria and factors of the studies
Persons who visited an urologist on odd days of the months and were prescribed a standard dosage of trospium chloride (5e15 mg twice a day) as monotherapy for a prolonged period by the urologist were included in the studied group. The inclusion criterion was the presence of any of the following diagnoses: OAB (N32.81), urge incontinence (N39.41), mixed incontinence (N39.46), and nocturia (R35.1). 16 The examination of cognitive function was conducted at the start of the study using the Montreal Scale. If a patient gained < 20 points, he/she was excluded from participation in the experiment.
In the course of the experiment, changes in the condition of patients' lower urinary tract were controlled with the use of overactive bladder questionnaire short form (OABq-SF) and uroflowmetry (at the start and 1 st and 2 nd control points), and also bladder diaries that were filled in on a daily basis. 17 Columns for filling in information about down-lying time, time of falling asleep, time of awakening due to the desire to urinate, amounts of consumed liquid, caffeine, alcohol, and smoked cigarettes, and the time of trospium intake were added to bladder diaries. We considered three or more episodes of urinary incontinence a day as evidence of LUTS severity. 18 At the start of the study, all participants were made aware of and given adequate information on the nature of dysfunction of accumulation and urine evacuation in LUTS, trospium's mechanism of action on the body, as well as its dosage regimen. A total of 441 (52.3%) patients used this option. At the end of the experiment, a comparative analysis of percentages of informed patients among groups with different compliance levels was conducted.
Besides, factors such as Charlson Comorbidity Index. 19 forms of associated diseases, number of used dosage forms, and awareness of LUTS therapy methods 14, 20 were studied using the analysis of individual outpatient medical records of patients and questionnaire surveys.
A study on demographic, social, and economic properties was carried out using a questionnaire survey, a financial statement analysis (certificate of income issued by tax office), and copies of academic certificates.
Annual income and average monthly income; average relation between pension and living wage; monthly costs of trospium and other drugs, as well as their squared values; and percentages of such costs in total patient costs and their squared values were considered as social and economic factors. Percentages of persons with an income level below the living wage, and those dealing with physically demanding jobs and exposed to hazardous conditions during their labor activities were calculated. 21 Levels of income and expenses are shown with reference to inflation against the United States dollar value as of April 2012.
Exclusion criteria were the presence of oncological diseases in their end stages, intake of AM drugs 6 months prior to the start of this study, and the status of being employed.
Compliance and stamina estimation
A trospium-treatment-free period of 30 days during the observation period was considered as a patient stamina criterion. The level of stamina and compliance were separately calculated for each potential factor affecting patient behavior. The average level of patient stamina was defined as the percentage of days, in observation period, during which the patient was acting in accordance with the recommendations of the attending physician. To compare the impacts of heterogeneous factors on treatment compliance, patients were split into three basic cohorts: consistent members (compliance rate of ! 80%), moderately consistent members (! 50e<80%), and poorly consistent members (< 50%). 22 
Statistical analysis
A 30-day treatment-free period expectation model was used for the estimation of compliance level. To create this model, threeparameter Weibull distribution accompanied by first-type double right censoring (relevant to the 1 st and 2 nd control points) was used. Adjustment of distribution to actual data was carried out using the HollandereProschan criterion.
The impacts of demographic, social, economic, and medical factors stipulated in Clause 2.2 were estimated during the analysis of models with simple gamma distribution and a log-link function. The important factor of control for persons with different compliance levels was carried out separately, with further comparison of results. In addition, estimation of contingency of independent variables was carried out using two-parameter regression models. In a number of cases, the Spearmen rank correlation coefficient was calculated for determining the degree of correlation between changes in parameters.
Differences were considered as significant at р < 0.05, while all p values were two sided.
All statistical analyses were performed using SAS version 8.0.2 (SAS Institute Inc., Cary, NC, USA).
Ethical principles
When creating and implementing experimental design, our research group followed the principles of the Declaration of Helsinki. All the participants of the experiment submitted written informed consent to participation. The research protocol was approved by the local ethics committee prior to the experiment.
Results
After 3 months, 66.5% and 44.0% of patients remained compliant with trospium treatment for 6 months and 1 year, respectively. The average time of reaching the 30-day trospium-treatment-free period was 191 days. Mild cognitive impairments were noted in 19.1% of patients before the start of the experiment (average points, 24.3 ± 2.7). The number of the Montreal Scale points scored by the other patients met the norm. The average points for the entire sample were 27.7 ± 2.9.
The percentage of married persons who stay within the city municipal district and have high educational qualification turned out to be significantly higher in the cohort of consistent patients (a significant difference of 0.05 for all cases; Table 1 ).
The total annual income and costs of medical services in the cohort of patients with a high compliance rate turned out to be significantly higher than those in the other cohorts. The average monthly income and auxiliary income level differed in groups of minimum and maximum stamina (p 0.05 and p 0.01, respectively). Other parameters were statistically close between cohorts ( Table 2 ).
The compliance rate was substantially higher among patients with higher income and those spending a small share of income on trospium costs. Impact of income level (p < 0.05) and its squared value (p < 0.01) in the regression model was statistically significant. The impact of both the percentage of trospium costs and the squared value of such costs on the compliance rate in the regression model was also substantial (p < 0.01 and p < 0.01, respectively). The impact of income level was substantially higher among elderly persons suffering from urge incontinence (27.8e35.5%) and OAB (31.2e39.4%) than among people with other diagnoses (Figure 1 ).
In the cohort of stable patients, the number of caffeine abusers was significantly low (p 0.01). In the same cohort, the percentage of individuals informed about the nature of the disease and the impact of trospium on the body was significantly higher (77.5%) than that in the other groups (p 0.01 and p 0.01, respectively; Table 3 ).
The average number of points of role physical (RР), social functioning (SF), role emotional (RE), and mental health (MH) values among persons with a high compliance rate at control points turned out to be significantly higher than that at the start of the study.
In the course of the experiment, it was found that in 69.4% of individuals with long-term treatment of trospium, some form of urinary incontinence was verified (OAB at 30.6%; Table 4 ). An analysis conducted after the end of the experiment showed that the percentage of compliance was significantly higher among individuals diagnosed with OAB. The result of comparison of compliant patient percentages in the subgroups with other diagnoses was statistically homogeneous.
Severe inconsistence symptoms prevailed among consistent patients (70.8%).
According to the OAB-SF questionnaire data, the average number of points assigned during the estimation of urgency and nighttime urination at the end of the experiment significantly differs between cohorts of consistent and inconsistent patients (p 0.05). The average number of points assigned during the estimation of urinary inconsistence episodes among consistent patients turned out to be significantly smaller than that in the cohort of poorly consistent (p 0.01) as well as moderately consistent (p 0.05) patients. Similar changes were detected during the estimation of urodynamic condition with the use of bladder diaries. The average urine volume flow rate among consistent patients turned out to be significantly higher than that among the patients of other cohorts (p 0.05), while the average bladder volume at the end substantially exceeded the bladder volume of inconsistent (p 0.01) and moderately consistent (p 0.05) patients ( Table 5 ). In total, 124 patients (14.7%) involved in the study discontinued their participation due to intolerable side effects. Of these, 14 (1.7%) were from the group with the highest compliance level, 54 (6.4%) from the group with middle compliance, and 56 (6.6%) from Table 1 Sociodemographic characteristics of persons !60 years of age receiving trospium (n ¼ 843).
Parameters
Level of adherence p the group with low treatment compliance. "Dry mouth" symptom was noted in 59 patients (7.0%), and in the group of treatmentcompliant patients, it was identified only in five cases (0.6%). "Vomiting" symptom was found to have the second highest frequency of occurrence; it was noted in 27 patients (3.2%). Symptoms such as blurred vision, constipation, rash, dry skin, and others were noted in 54 patients (6.4%). Nine percent of patients of the cohort comprising those with a medium compliance rate and 11.5% of those comprising poorly consistent patients mentioned intolerable dry mouth as the reason to decline further treatment.
In the cohort of stable patients, the percentage of individuals refusing treatment because of intolerable side effects appeared to be the lowest.
Discussion
A significant prevalence of married and highly educated patients who stay in cities, and have high annual income and costs of medical services was detected in the cohort of highly compliant persons. Calculation of regressive influence models could determine the substantial impact of income levels and their squared values, and also percentages of income and its squared values, which patients spend on trospium purchase, on treatment compliance.
The percentage of consistent patients who are aware of the nature of the disease and its treatment methods turned out to be substantially higher than that in other cohorts, while the percentage of caffeine abusers turned out to be significantly lower. Significant increases in points of RР, SF, RE, and MH values that describe health influence on the quality of life were reported for persons compliant with the treatment. The most widespread diagnosis among consistent and moderately consistent patients turned out to be OAB (35.9%) and urge incontinence (43.5%), respectively. Persons who suffer from severe urinary inconsistence symptoms (70.8%) significantly prevailed in the cohort with Bold emphasizes the significance of the differences. a Total percentage of urge, mixed, and nocturnal incontinence, and OAB in total exceeds 100% due to the fact that a combination of these diseases may occur in one person. b Efficacy of treatment indicates the number of patients with a score of 8 according to OABqeSF (overactive bladder questionnaire short form) and normal uroflowmetry results after the 6 th month (1 checkpoint; N ¼ 492) and 12 th month (2 checkpoints; N ¼ 371) of observation. treatment compliance of ! 80%. High treatment efficacy was reported in cohorts of consistent and moderately consistent patients. Thus, in general, our results correlate well with the data of other researchers. One study indicated that the average time prior to rejection of treatment with AM drugs is 159 days. 23 In our study on the duration of trospium intake, this value was 191 days, which could probably be explained by some of its pharmacological effects, particularly the absence of any adverse impact on the central nervous system and high effect selectivity. These assumptions are confirmed by the data of other research groups on higher level of trospium treatment compliance among persons of different age strata. 24 There are singular reports regarding side effects and poor results as the main reasons for treatment rejection in the relevant literature 10, 11 ; yet they correlate neither with our results nor with most researchers' point of view. According to our data, only 14.5% of patients in the whole scope of selection rejected trospium treatment or interrupted it due to intolerable side effects, with similar percentages being reported by many other researchers. 24e26 There are virtually no data on the dependence between severity of symptoms and forms of disorders in available studies. Meanwhile it is reported that the patients with severe symptoms have a high adherence to receive medication. It could be due to abrupt worsening of the quality of life related to the health of such patients. It is also confirmed by substantial changes in RР, SF, RE, and MH values among patients with high level of compliance during the course of treatment. The impact of an excessive amount of caffeine on the emergence of OAB symptoms is considered to have been studied; yet we have established that moderate caffeine consumption is a factor that correlates with high level adherence of trospium treatment.
When analyzing the impacts of comorbidity and taking of other medicinal products on trospium treatment compliance, we obtained results that were somewhat different from the data of other researchers. There is information that polymorbidity is able to cause supporting effect to the compliance of taking medicinal products, as it often involves taking multiple medications. 10 It can be assumed that taking of some of these products is directly related to the current state of health and acts as an incentive reminder to take an entire pool of drugs. According to other sources of information, in polypharmacy, many patients tend to ignore a part of the prescribed medications, reducing an excessive medication load at their own discretion. 13 The protocol of our study had no clause on a special study of polypharmacy as a predictor of compliance (e.g., level of compliance with different numbers of drugs). However, according to our data, the percentage of patients with multiple diseases who took several medicines was proved to be very high in all three groups with different levels of trospium treatment compliance (84.1e96.0%). This is probably due to the fact that, with an average age of 67.1e73.7 years, most patients in the groups had a high prevalence of polymorbidity and some other reasons for refusal, for instance, financial difficulties or excessively critical attitude to minor side effects. Certainly, we are aware that this information is insufficient for rational conclusions, and the matter requires further investigation.
In our study, we have made an attempt to compare the importance of heterogeneous factors for drawing behavioral decision by patients who take trospium for a long period of time to treat various forms of LUTS. We have been observing a substantial volume of patients throughout a year, which allowed us to analyze and compare the levels of demographic, social, economic, and medical compliance-related factors. In our opinion, the obtained results could be used for practical healthcare when analyzing appropriateness of trospium prescription to patients with different social, economic, and medical properties.
Conclusions
This prospective randomized study has shown that the impact of various medical, social, demographic, and economic factors on trospium treatment compliance among patients over 60 years is uneven. The average time of reaching the 30-day trospiumtreatment-free period was 191 days. The percentages of patients who remained compliant for 6 months and 1 year were 58.3% and 44.0%, respectively.
Highly educated city dwellers who are married, have comparatively high annual/monthly income and costs of medical services, and spend a small percentage of income monthly trospium costs prevailed in the cohort of consistent patients. Consistent patients were better aware of the nature of their disease and were not caffeine abusers; they also showed substantial positive changes in health condition indices such as RР, SF, RE, and MH values at the end of the experiment. Among patients who were committed to treatment to have the largest percentage suffering from OAB, severe urinary inconsistence symptoms, and high treatment efficacy, which was confirmed by changes in urodynamic values, while significantly smaller percentage of side effects compared with other cohorts was reported.
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